Evidence map›Paper›PMID 36138043›Full record

ArticleNature communications2022

IL-23 signaling prevents ferroptosis-driven renal immunopathology during candidiasis.

Nicolas Millet, Norma V Solis, Diane Aguilar, Michail S Lionakis, Robert T Wheeler, Nicholas Jendzjowsky, Marc Swidergall

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Journal of fungi (Basel, Switzerland) · 2025
    Article
  11. Article
  12. Role of ferroptosis in chronic kidney disease.Cell communication and signaling : CCS · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. A New Phenotype inmBio · 2023
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Nicolas MilletDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA.ORCID 0000-0002-4644-7153
Norma V SolisDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA.
Diane AguilarThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Michail S LionakisFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.ORCID 0000-0003-4994-9500
Robert T WheelerDepartment of Molecular and Biomedical Sciences, University of Maine, Orono, ME, USA.ORCID 0000-0003-3223-7021
Nicholas JendzjowskyThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.ORCID 0000-0002-4342-1839
Marc SwidergallDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA, USA. mswidergall@lundquist.org.ORCID 0000-0002-5261-6267
UCLA Medical Center · USUniversity of California, Los Angeles · USNational Institute of Allergy and Infectious Diseases · USUniversity of Maine · US

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
Oral commensal fungi and structural immunityR01DE031382 · NIDCR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Marc Swidergall · 2022 to 2026
$2.5M
Novel Candida albicans host receptors during infection and immune responseR00DE026856 · NIDCR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SWIDERGALL, MARC · 2019 to 2021
$710k
Unraveling transcriptomic and functional changes to immune sensing neuronal ganglia in response to allergy and bacteriaR21AI159221 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI JENDZJOWSKY, NICHOLAS · 2022 to 2023
$438k
Intravital study of innate immunity to mucosal candidiasisR15AI133415 · NIAID · UNIVERSITY OF MAINE ORONO · PI WHEELER, ROBERT T. · 2018 to 2018
$415k
NCATS NIH HHS KL2 TR001882NIAID NIH HHS R15 AI133415NIAID NIH HHS R21 AI159221NIDCR NIH HHS R00 DE026856NIDCR NIH HHS R01 DE031382
6 · The paper itself

Abstract

During infection the host relies on pattern-recognition receptors to sense invading fungal pathogens to launch immune defense mechanisms. While fungal recognition and immune effector responses are organ and cell type specific, during disseminated candidiasis myeloid cells exacerbate collateral tissue damage. The β-glucan receptor ephrin type-A 2 receptor (EphA2) is required to initiate mucosal inflammatory responses during oral Candida infection. Here we report that EphA2 promotes renal immunopathology during disseminated candidiasis. EphA2 deficiency leads to reduced renal inflammation and injury. Comprehensive analyses reveal that EphA2 restrains IL-23 secretion from and migration of dendritic cells. IL-23 signaling prevents ferroptotic host cell death during infection to limit inflammation and immunopathology. Further, host cell ferroptosis limits antifungal effector functions via releasing the lipid peroxidation product 4-hydroxynonenal to induce various forms of cell death. Thus, we identify ferroptotic cell death as a critical pathway of Candida-mediated renal immunopathology that opens a new avenue to tackle Candida infection and inflammation.

Indexed as

CandidiasisFerroptosisAnimalsAntifungal AgentsCandida albicansEphrinsInflammationInterleukin-23MiceMice, Inbred C57BLAntifungal AgentsEphrinsInterleukin-23

Identifiers

PMID36138043
PMCPMC9500047
OpenAlexW4296634061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.